Jasper Therapeutics Launches Warrant Buyback at $0.324 Per Unit

Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced Tuesday it has launched a formal offer to purchase all outstanding warrants tied to its September 2025 underwritten public offering, paying holders $0.324 in cash per warrant with no interest attached.

The Redwood City, Calif.-based clinical-stage biotechnology firm said the buyback is designed to shrink the pool of shares that could eventually be issued if warrant holders exercised their rights, a move intended to curb potential dilution of existing shareholders. Any warrants tendered under the offer will be permanently retired and cancelled rather than reissued.

Read more Badass Capital Fund I Posts 39.92% Net Return in Q3 2026 →

The company framed the transaction as a capital-structure clarification measure, arguing that reducing the overhang of unexercised warrants gives both current shareholders and prospective investors a clearer picture of how many shares could ultimately be outstanding. Warrant dilution is a persistent concern in biotech financings, where companies frequently raise capital through bundled stock-and-warrant packages.

Jasper focuses on developing therapies for immune-mediated diseases and remains in the clinical stage, meaning it has not yet generated product revenue. Capital structure management moves such as this warrant tender are common among pre-revenue biotechs seeking to maintain investor confidence ahead of further fundraising or partnership discussions.

Continue reading at GlobeNewswire - Industry News on Financial Services.